IIFL Securities's Stock Idea: Buy Gland Pharma with Target Rs 2250

IIFL Securities recommends buying Gland Pharma at its current market value of Rs 2172.6 on July 31. Based on their analysis, the target price for Gland Pharma has been set at Rs 2250. This price target represents a potential upside of around 3.5% from the current market price. The buy recommendation is likely driven by the company's strong fundamentals and growth prospects in the pharmaceutical industry.

About Gland Pharma:

Gland Pharma Limited is an Indian pharmaceutical company headquartered in Hyderabad, Telangana. It is one of the largest manufacturers of generic injectable products in India and the world. The company's product portfolio includes a wide range of injectable formulations, including antibiotics, cardiovascular drugs, anti-infectives, and oncology products. Gland Pharma has a global presence with manufacturing facilities in India, China, and the United States. The company's products are marketed in over 60 countries worldwide. Gland Pharma is listed on the National Stock Exchange of India (NSE) and is a constituent of the Nifty 500 index.

52 Week Price Trend:

Gland Pharma's current market price (CMP) of Rs 2172.6 is near its 52-week high of Rs 2195.75. This indicates that the stock has been on a strong uptrend recently. However, it is important to note that the stock has also experienced a significant decline in the past year, with its 52-week low being Rs 861. Investors should therefore exercise caution before investing in this stock and consider factors such as the company's financial performance, industry outlook, and overall market conditions.

Stratzy's MOST Analysis:

Stratzy's MOST framework assigns a rating of BB- to GLAND. This indicates a Medium Fundamental Risk based on the evaluation of four pillars: Management, Outlook, Safety, and Trend. The BB- rating suggests that GLAND faces moderate uncertainties or challenges in one or more of these areas, requiring investors to exercise caution and conduct further due diligence before investing heavily in the stock.

Fundamental and Technical information provided in this blog were last updated on 31 Jul, 2024

Disclaimer: The information and recommendations presented in this section, including any attached reports, are sourced from third-party providers through diverse channels. The views and opinions expressed within these materials belong solely to their respective creators. These views and opinions do not necessarily reflect the position of Stratzy Fintech Pvt Ltd. Stratzy explicitly disclaims any guarantees, express or implied, regarding the accuracy and reliability of the provided content. We strongly advise consulting with a licensed financial advisor before making any investment decisions based on this information. Remember, seeking independent financial advice is crucial.